Kornimate/medical-research-clean huggingface dataset:
clinical performance comparison of 2 theranova 400 dialyzer prototypes in hd with high-flux dialyzers in hd and hv hdf mode

Conditions: End Stage Renal Disease

Summary: the study investigates the performance of a new dialyzer (theranova 400) containing a membrane with increased pore sizes. the performance will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. two different theranova 400 prototypes (aa and bb) operated in hemodialysis mode will be compared with a cordiax fx-80 dialyzer, operated in hemodialysis mode, and with a cordiax fx-800, operated in high volume hemodiafiltration mode. safety events and albumin loss into the dialysate will be monitored


Eligibility criteria:
inclusion criteria: 1. patient has end-stage renal disease (chronic kidney disease stage 5d) 2. patient is 18 years of age or older 3. patient is male or female 4. patient, if female, is non-pregnant; and if capable of becoming pregnant, will be using a medically acceptable means of contraception during participation in the study 5 .patient has been receiving hd or hdf therapy for \>3 months prior to study enrollment and is expected to survive for at least 12 months after enrollment. 6. patient has a stable functioning native fistula 7. patient is willing to comply with the study requirements for therapy during the entire study treatment period 8. patient is capable fo providing written informed consent to participate in the study exclusion criteria: 1. patient is undergoing single-needle dialysis 2. patient has an known abnormal k/λ ratio (less than 0.37, or greater than 3.1) 3. patient has a known active infection and is currently receiving antibiotic treatment 4. patient has known active cancer 5. patient has a known positive serology test for human immunodeficiency virus (hiv) or hepatitis b,c or e 6. patient has a known serious hemostasis disorder 7. patient has a known monoclonal gammopathy 8. patient has a known polyclonal gammopathy 9. patient has a unstable condition as judged by the treating physician based on medical history, physical examination and laboratory testing including (but not limited to) any of the following: * myocardial infarction within the last 3 months * tachyarrhythmia or bradyarrhythmia absoluta * unstable angina pectoris * left ventricular ejection fraction \<30% * significant pericardial disease 10. patient has any other known comorbidity that could, in the opinion of the investigator, potentially conflict with the study purpose or procedure 11. patient has a known significant psychiatric disorder or mental disability that could interfere with the patient's ability to provide informed consent and/or comply with protocol procedures 12. patient has a history of non-compliance with the dialysis prescription, as assessed by the investigator 13. patient has participated in another interventional clinical study in the past 3 months, or is currently participating in another interventional clinical study
left atrial remodelling in hypertension: effects of ramipril or irbesartan

Conditions: Left Atrial Volume; Hypertensive Heart Disease; Antihypertensive Drugs; Diastolic Function; Renin Angiotensin System

Summary: aim of the study is to compare in hypertensive patients the effect of one year therapy with ace-inhibitor (ramipril) or angiotensin ii receptor blocker (irbesartan) on left atrial remodelling and diastolic function.


Eligibility criteria:
inclusion criteria:· * mild to moderate essential hypertension * no antihypertensive treatment * good quality echocardiogram exclusion criteria: * cardiovascular diseases (ami, stroke o tia) * heart failure, valvular heart disease * diabetes * secondary hypertension * atrial fibrillation * hepatic and renal severe failure * pregnancy

Keywords: left atrial volume hypertension ramipril irbesartan diastolic function
characterization and progression of minor phenomena in parkinson's disease (pd)

Conditions: Parkinson Disease; Parkinson Disease Psychosis; Hallucinations; Delusion

Summary: parkinson's disease psychosis encompasses a range of symptoms, including minor phenomena, frank hallucinations, and delusions. minor phenomena include passage hallucinations (fleeting sense of a person, animal or object passing in the periphery), presence hallucinations (feeling of nearby presence), and illusions (misrepresentation of external stimuli). some forms of pd psychosis may be progressive. the primary objective of this study is to: 1) to determine the cumulative probability of developing hallucinations or delusions over time in individuals with pd minor phenomena followed for 36 months.


Eligibility criteria:
inclusion criteria: * parkinson's disease (as determined by movement disorders society diagnostic criteria for clinically probable parkinson's disease) * parkinson's disease minor phenomena * ≥30 years of age * proficient in english * willing and able to provide informed consent exclusion criteria: * any current or prior history of formed hallucinations or delusions * current or prior treatment with an antipsychotic medication (regardless of indication) * diagnosis of mania with psychotic features, bipolar or related disorder, depression with psychotic features, or a psychotic disorder * unable or unwilling to complete study activities * any medical or psychiatric comorbidity that, in the opinion of the investigator, would compromise study participation
anti-estrogen therapy for hereditary hemorrhagic telangiectasia a double-blind placebo-controlled clinical trial

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: hereditary hemorrhagic telangiectasia (hht) is associated with recurrent epistaxis in 90% of cases. good response to hormone treatment has been documented, although its use remains controversial. a double-blind placebo-controlled trial with estrogen treatment did not show any benefit over placebo. the aim of this study is to examine the efficacy of an antiestrogenic agent, tamoxifen, in the treatment of hht-associated epistaxis. the study will include up to 60 patients, over 18 years old.

patients with hht-related epistaxis who will attend our center will randomly be assigned to 6 months of treatment with either tab. tamoxifen 20 mg once daily or placebo. the group will included both men and women over the age of 18 years. a detailed medical history will be taken at presentation. all patients will be examined by an otolaryngologist before and during the trial to assess the nasal condition and telangiectases and blood clots in the airway, nasal and oral cavity, and body skin. blood will be collected for blood count and measurement of clotting time and liver function at onset of the trial and once monthly during treatment. patients will be requested to complete a daily chart describing the course of their epistaxis, and female patients will be referred for gynecologic follow-up, including ultrasound. evaluations will be conducted once a month throughout the treatment period. the study was approved by the ethics committee of rabin medical center. all patients will sign a consent form.

Eligibility criteria:
inclusion criteria: * patients suffering from hht with severe epistaxis * over 18 years old exclusion criteria: * under 18 years old * pregnancy * treatment with anticoagulance * treatment with hormones

Keywords: hht epistaxis tamoxifen hemoglobin
rapid: a comparison study of a novel ultrasound device of automated congenital heart imaging

Conditions: Congenital Heart Disease

Summary: the rapid ultrasound is a portable imaging device that captures a one point image from the subcostal region of the heart. the device is set on the patient's chest and captures the image in \&lt;1 minute. it uses ultrasound imaging energy that is similar to commercialized devices and safe for patients of all ages and sizes. the device is a non-significant risk and therefore will not require an ide. images from rapid will be taken directly before or after the standard clinical pcu. images taken from both the rapid device and the standard pcu will be de-identified and stored securely in box for review by two independent cardiologists. image reviews will be conducted within box.


Eligibility criteria:
inclusion criteria: * \<1 years old * be a patient at masonic children's hospital or masonic children's heart center clinic undergoing pcu exclusion criteria: * open chest * on ecmo * deemed medically unstable by care team * cardiology, icu, hospitalist or bedside nurse concerns
validating immunological markers associated with mental fatigue in graves' disease

Conditions: Graves Disease; Mental Fatigue

Summary: mental fatigue occurs in many diseases and the reasons are mostly unknown. the investigators hypothesize that remaining mental fatigue after restored euthyroidism in graves' disease is an autoimmune complication. this is a confirmatory study of the biomarkers from immunograves wp1 in which immunological markers with possible association with mental fatigue in graves' disease are explored. in immunograves wp2, 310 patients with graves' disease are assessed for symptoms of mental fatigue, quality of life, anxiety and depression, self-evaluated stress, coping strategies, personality traits, eye symptoms and background variables. participants are examined in hyperthyroidism at inclusion, within three weeks from diagnosis, and in euthyroidism after 15 months. serum and cerebrospinal fluid (in a subsample of participants) is collected at both visits and will be evaluated for the immunological markers identified in wp1 as well as for thyroid hormones, thyroid autoantibodies and biomarkers indicating organic and structural nerve damage. significant predictors for mental fatigue will be identified by logistic regression. to assess functional changes in the brain, magnetoencephalography will be performed in a subset of patients and in healthy controls at inclusion and after 15 to 18 months. combined with magneto resonance imaging (mri), magnetoencephalography gives information on neuronal activation during attention testing.


Eligibility criteria:
inclusion criteria: * recently diagnosed graves' disease * positive thyroid stimulating hormone (tsh)-receptor antibodies (trab) * thyroid hormones above the upper reference limit * inclusion within three weeks after start of antithyroid drugs controls: matched for gender and age exclusion criteria: * person unable to follow protocol as with psychosis, dementia or not able to answer questionnaires in swedish. * recidive of graves' disease * pregnancy controls: -thyroid disease * neurological disease
occurrence of bleeding and thrombosis during antiplatelet therapy in non-cardiac surgery

Conditions: Bleeding; Thrombosis; Cardiac Events

Summary: research questions: 1. what is the absolute risk reduction for in-hospital major adverse cardiac events (mace) associated with the use of dual anti-platelet therapy as compared with aspirin alone in this population? 2. what is the absolute risk increase for clinically significant bleeding during the same period associated with the use of dual anti-platelet therapy as compared with aspirin alone in this population? in brief the design of the study is as follows: * we will study patients undergoing non-cardiac surgery within four years of coronary stenting. * we will record the anti-platelet agents taken by patients before, during and after surgery. * we will record cardiac and bleeding events that occur whilst the patient is in hospital. * we will use the statistical technique of propensity scoring to match patients who have similar risk factors and who received different anti-platelet regimens. * we will compare the incidence of cardiac events and bleeding in the matched groups.

this study will compare the use of aspirin alone with dual antiplatelet therapy (i.e. aspirin and clopidogrel) in patients presenting for elective non-cardiac surgery who have undergone pci with either bare metal stent or drug eluting stent placement in the four years prior to surgery. the absolute risk reduction in major adverse cardiac events (mace) with dual antiplatelet therapy and the absolute risk increase for clinically significant bleeding events with dual therapy will be determined. this will allow the number needed to treat (nnt) for the prevention of mace and the number needed to harm (nnh) for bleeding to be determined and the optimal antiplatelet therapy in this setting to be identified.

Eligibility criteria:
inclusion criteria: * patients undergoing non-cardiac surgery within four years of percutaneous coronary intervention (pci) with the placement of a bare metal or drug eluting stent will be included in the study. exclusion criteria: * patients maintained on anticoagulant therapy e.g. heparin infusion before and after surgery will be excluded. (patients receiving prophylactic doses of heparin for prevention of thromboembolic events will be eligible for inclusion.) * patients receiving bridging therapy with full anticoagulant does of heparin or other drugs to compensate for the withdrawal of antiplatelet drugs will be excluded. * patients who are anticoagulated with warfarin (inr\>1.5 at the time of surgery) will be excluded. * patients receiving full anticoagulation with heparin for a known recent a known thromboembolic event (appt ratio \> 1.5) be excluded. -

Keywords: prospective observational study major adverse cardiac events (mace) clinically significant bleeding events dual anti-platelet therapy aspirin alone therapy non-cardiac surgery percutaneous coronary intervention (pci) placement of a bare metal or drug eluting stent obtain simon howell esa european society of anaesthesiology
drug interaction study with famotidine, atazanavir, and atazanavir/ritonavir/tenofovir

Conditions: HIV Infections

Summary: the purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famotidine results in atazanavir exposures similar to those when atazanavir/ritonavir/tenofovir 300/100/300 mg is dosed without famotidine in healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects between the ages 18 to 50 years old with a bmi 18 to 32 kg/m2

Keywords: hiv protease inhibitor
value of cortactin expression in invasive and non-invasive urinary bladder urothelial carcinoma in egyptian population

Conditions: Urothelial Carcinoma

Summary: urothelial carcinoma is the ninth most common malignant neoplasm worldwide. nearly in all human tumors, actin filaments are involved in lamellopodia or cellular extensions. cortactin is involved in fixing the actin assembly to enhance cellular penetration. assessment of cortactin expression in invasive and non-invasive urothelial carcinoma and recording any significant different expressions may have benefits in developing more effective anticancer chemotherapeutic agents.

bladder carcinoma is the 9th most prevalent cancer worldwide. mostcases are diagnosed in men. bladder carcinoma is categorized into three disticly different categories; non- muscle invasive, muscle invasive and metastatic bladder carcinoma. vast majority of all bladder carcinomas are diagnosed as urothelial carcinoma (uc). squamous cell carcinoma (scc), adenocarcinoma and other rare types represent the remaining 10%. in egypt, bladder carcinoma is ranked as the most prevalent cancer . the most important etiological causes for such disease in egypt are festation by s. haematopium and cigarette smoking. cortactin is a 63-65 kda protein, encoded by a gene located on 11q13. cortactin activates and binds to arp2/3 and stabilizes the branched actin networks. invadopodia are actin-rich cellular protrusions, associated with enhanced proteolytic activities in the invasive regions of carcinomas. it is also incorporated in invadopodia, cortactin expression is enhanced once or rapidly following secretions of transmembrane metalloproteinase, mt1-mmp. extracellular matrix (ecm) proteolytic cleavage develops soon after secretion of mt1-mmp and cortactin. increased secretion of cortactin was studied in a lot of malignant tumors, including melanoma, mammary, pancreatic duct, hepatocellular and colorectal adenocarcinomas.

Eligibility criteria:
inclusion criteria: * patients with primary urinary bladder carcinoma. exclusion criteria: * patients received chemotherapeutic agents.

Keywords: cortactin urothelial carcinoma
new diagnostic markers in dignosis of complicated appendix

Conditions: Complicated Appendicitis

Summary: most common cause of acute abdomen is acute appendicitis delay dignosis of acute appendicitis lead to complications as perforation this study examined efficacy of hyperbilirubinemia\&hyponatremia as indicator of complicated appendicitis


Eligibility criteria:
inclusion criteria: * all patient admitted for acute appendicitis underwent surgery and post operativly confirmed histopathology of acute appendicitis exclusion criteria: * patient with liver disease liver transplantation chronic alcoholism congental biliary disease pregnancy appendicular neoplasm hemolytic disease hepatocellular carcinoma
cultural adaptation of the tim&sara prevention program

Conditions: Depressive Symptoms

Summary: disparities between african-american and european-american youth regarding academic outcomes, mental health, and physical health exist. depression, a very common mental health problem, plays a central role by impacting academic outcomes and cardiovascular health. thus, a program that successfully reduces the likelihood for youths to develop depression should also reduce problems with academic outcomes and physical health and therefore reduce disparity in all three domains. research demonstrates that european-american youth benefit more from programs preventing the development of depression than their african-american peers. thus, the goals of this project are to (a) identify mechanisms that may result in differential program effectiveness across racial groups, and (b) adapt such a program (tim\&sara) so youth from diverse racial backgrounds benefit similarly. freshmen in an urban high-school will participate in tim\&sara, fill out surveys and give biological data in saliva.

already in adolescence, substantial disparities between african-americans and european-americans regarding academic outcomes, mental health, and physical health like cardiovascular health exist. while these domains are often treated as unrelated, they influence each other in a way that the disparity in one variable increases the likelihood for disparity in the others. depression, a very common mental health problem, plays a central role by impacting academic outcomes and cardiovascular health. thus, a program that successfully reduces the likelihood for youths to develop depression should also reduce problems with academic outcomes and physical health and therefore reduce disparity in all three domains. unfortunately, research demonstrates that european-american youth benefit more from programs preventing the development of depression than their african-american peers. thus, the main goals of this research project are to (a) identify mechanisms that may result in differential prevention program effectiveness across youth race groups, and (b) adapt such a program (tim\&sara) so youth from diverse racial backgrounds benefit similarly. in this project, the depression prevention program tim\&sara will be implemented as part of the normal school curriculum for freshmen in an urban high-school. the differential effects of the program on african-american and european-american youths will be examined using surveys and biological data in saliva.

Eligibility criteria:
inclusion criteria: * 9th grade students in the participating high school exclusion criteria: -
factors associated with radiographic pathophysiology for trapeziometacarpal arthrosis in patients not seeking care for this condition

Conditions: Trapeziometacarpal Arthrosis

Summary: the investigators are doing this research study to discover factors, such as job, hobbies, or race that are associated with arthrosis at the base of your thumb on x-rays. thumb arthrosis is one of the most common kinds of arthritis. about 116 people will take part in this research study at massachusetts general hospital (mgh).


Eligibility criteria:
inclusion criteria: * 55 years and older * not seeking care for tmc arthrosis from hand surgeon at the time of visit * english fluency and literacy exclusion criteria: -
management of open fracture tibia in teenagers

Conditions: Open tíbia Fracture

Summary: the aim of this study is to study the incidence of open tibial fractures in early teenagers and evaluate the management outcomes

tibial fractures are the third most common long bone fracture after the femur and forearm, representing 15% of all pediatric fractures tibial fracture is a common injury in children, and it usually involves the diaphysis and distal metaphyseal region open fracture tibia must be considered orthopedic emergencies due to the high risk of contamination, osteomyelitis, malformation, nonunion, and disability the anteromedial aspect of the tibia is subcutaneous with no overlying musculature for protection and the middle/distal tibia has no muscular origins, which can delay union in these areas the biology of the repair of fractures in children differs from that in adults in several ways. the soft tissues have excellent healing capacity, uncontaminated devitalised bone is salvageable and periosteum in children can regenerate bone in the presence of bone loss. union is faster. modalities of treatment of open fracture tibia in teenagers including closed reduction followed by a well- molded casting ,debridement followed by casting , utilization of external fixator (ef) remains a popular choice for open injuries, severely comminuted and unstable fractures and those with significant soft tissue or vascular injury require external fixation however, pin tract infection (pti) and refracture are common complications during the application of ef . elastic nail has also been reported with an acceptable for the treatment of open tibial fractures , open reduction and internal fixation (orif) was reserved for situations in which an adequate reduction could not be obtained or maintained by conservative, also closed reduction and intramedullary nail fixation appropriate for the treatment of extraarticular distal tibial fractures .

Eligibility criteria:
inclusion criteria : • all patients presenting with isolated open fracture tibia in teenagers (aged 10 to 19 years old ) exclusion criteria: * patient who refuse to participate in the study * patient less than 10 or more than 19 years old * pathologic fractures * open fracture tibia with other bony or organ injury * open fracture tibia with soft tissue loss or vascular injury